M6-C Artificial Cervical Disc, Spinal Kinetics LLC: New monitoring requirements for the risk of osteolysis
Authored by Medicines and Healthcare products Regulatory Agency (MHRA)Originally published 15 Jan 2026
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Medical Professionals
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
The MHRA has conducted an assessment following reports of osteolysis and early device failure in the literature and is issuing new monitoring requirements for patients implanted with the M6-C artificial cervical disc.
Read the full update from MHRA
About MHRA alerts and recalls
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS and wider healthcare system. When new safety concerns are identified, or when issues arise with the manufacture or distribution of a medicine or device, the MHRA issues alerts and recalls to protect patients and support healthcare professionals.
These alerts can take several forms. Some provide updated guidance on prescribing or monitoring requirements for medicines and vaccines. Others may highlight newly recognised side effects, or remind clinicians of important risk-mitigation steps. In the case of medical devices, alerts may cover field safety notices, product recalls, or urgent device modifications. All of these communications are designed to ensure that products are used safely and that any risks are managed appropriately.
Patient.info republishes MHRA alerts and recalls so that this information is available quickly and accessibly to both healthcare professionals and the public. The summary above is taken directly from the MHRA’s official publication. To read the full advice, including detailed recommendations for prescribers, manufacturers and patients, please follow the “Read more” link to the MHRA website.
If you are a healthcare professional, you should consult the full notice to confirm the latest prescribing information, monitoring requirements and any actions you need to take in your practice. If you are a patient or carer, do not stop treatment or make changes to your medication or device without first seeking professional advice. If you have any concerns about your medicine or device, speak to your GP, pharmacist or specialist nurse.
Contains public sector information licensed under the Open Government Licence v3.0.
Patient picks for Alerts, recalls and safety information
%3A%20interim%20advice%20on%20risk%20mitigation%20measures%20following%20reports%20of%20deaths%20in%20patients%20while%20taking%20givinostat/og.png)
Professional
Duvyzat®▼ (givinostat): interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat
There have been several reports internationally of deaths in patients with Duchenne muscular dystrophy (DMD) while being treated with Duvyzat® (givinostat). Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices..
by Medicines and Healthcare products Regulatory Agency (MHRA)

Professional
Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction
New safety measures are now being implemented to improve how the risks of suicidal thoughts and behaviours and persistent sexual dysfunction are communicat... Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices..
by Medicines and Healthcare products Regulatory Agency (MHRA)

Professional
Neck pain
Psychological risk factors, such as long-term stress, lack of social support, anxiety, and depression are important risk factors for neck pain. Kazeminasab S, Nejadghaderi SA, Amiri P, et al; Neck pain: global epidemiology, trends and risk factors. BMC Musculoskelet Disord. 2022 Jan 3;23(1):26. doi: 10.1186/s12891-021-04957-4. 63334 : Neck pain:.
by Dr Colin Tidy, MRCGP
%3A%20Consider%20delayed%20administration%20of%20concurrent%20echinocandins%2C%20such%20as%20caspofungin%2C%20to%20reduce%20the%20risk%20of%20adsorption%20onto%20new%20polyacrylonitrile%20(PAN)-based%20filter%20membranes%20DSI%2F2026%2F014/og.png)
Professional
Continuous renal replacement therapy (CRRT): Consider delayed administration of concurrent echinocandins, such as caspofungin, to reduce the risk of adsorption onto new polyacrylonitrile (PAN)-based filter membranes DSI/2026/014
Continuous renal replacement therapy (CRRT) is used for managing severe acute kidney injury and fluid overload. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monit....
by Medicines and Healthcare products Regulatory Agency (MHRA)
%20and%20torticollis/og.png)
Professional
Neck pain (cervicalgia) and torticollis
... See also the separate Cervical spondylosis Cervical spondylosis and Whiplash and cervical spine injury Whiplash and cervical spine injury articles. (Epidemiology) Neck pain - cervical radiculopathy, NICE CKS, November 2023 (UK access only) 67326 : CKS Neck pain - cervical radiculopathy The global age-standardised prevalence rate of neck pain.
by Dr Philippa Vincent, MRCGP

Professional
Whiplash and cervical spine injury
Bragg KJ, Varacallo M; Cervical Sprain. There are two types of injury: Typical cervical hyperextension injuries occur in drivers/passengers of a stationary or slow-moving vehicle that is struck from behind. A rapid deceleration injury throws the head forwards and flexes the cervical spine. Whiplash-associated disorders (WAD) can be classified by.
by Dr Philippa Vincent, MRCGP
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.
Article history
Article also available in English, German, Spanish, French, Italian, Portuguese, Hindi, Hebrew, Arabic, and Swedish.
15 Jan 2026 | Originally published
Authored by:
Medicines and Healthcare products Regulatory Agency (MHRA)
More in alerts, recalls and safety information
- Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision
- Botulinum toxin type A products: updated warnings regarding risk of iatrogenic botulism
- Class 2 Medicines Recall: Crescent Pharma Limited, Ramipril 5mg capsules, EL(26)A/11
- Class 2 Medicines Recall: Norgine Pharmaceuticals Limited, Pedmarqsi 80 mg/mL solution for infusion, EL(26)A/42
- Class 2 Medicines Recall: Syri Limited, T/A SyriMed, Baclofen 10mg/5ml Oral Solution, EL(26)A/06
- Class 4 Medicines Defect Notification: Flamingo Pharma UK Ltd, Amitriptyline Hydrochloride 10mg, 25mg, 50mg Tablets, EL(25)A/52
- Class 4 Medicines Defect Notification: Lexon UK Ltd, Moclobemide 150mg tablets, EL(25)A/50
- Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
- Dräger Atlan Anaesthesia workstations: risk of ventilator failure (DSI/2026/005)
- NewDuvyzat®▼ (givinostat): interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat
- Field Safety Notices: 5 to 9 October 2026
- Field Safety Notices: 9 - 13 March 2026
- NewField Safety Notices: 9 to 13 November 2026
- Field Safety Notices: 13 to 17 October 2025
- Field Safety Notices: 14 to 18 September 2026
- Field Safety Notices: 22 to 26 September 2025
- Field Safety Notices: 28 September 2026 to 2 October 2026
- Filters should be used during the administration of Parenteral Nutrition for patients in all care settings DSI/2026/011
- Isotretinoin – updates to prescribing guidance and survey of services
- Nasal decongestant sprays and drops containing xylometazoline hydrochloride / oxymetazoline hydrochloride: increased risk of rebound congestion, rhinitis medicamentosa, and tachyphylaxis with overuse


